
British AI provider raises $33m in Series A financing
Existing investors Air Street Capital, Amadeus Capital Partners, and Partech also participated in the large Series A financing round. V7's platform...

ExeVir receives EIB risk finance for multiple COVID-19 nanobody
With the resurgence of COVID-19 in China, ExeVir BIO sees commercial potential in the future treatment of immunocompromised people, who make up 3%...

Evonetix extends Series B financing to US$54m
According to Evonetix Ltd, a benchtop gene synthesis specialist, the investment, which also includes existing investors such as Molten Ventures,...

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

Amsterdam Neogene Therapeutics aquired by AstraZeneca
Neogene Therapeutics is developing both patient-specific and shared neoantigen TCR programmes to deliver such TCRs into a patient's own T cells and...

Benefits of booster campaigns questionable
While Pfizer Inc and BioNTech SE financial outlooks in February prognosed more than $50bn in combined coronavirus disease (COVID-19) vaccine sales in...

Vésale Bioscience wins R&D grant
Under the grant provided by the EIC Accelerator Fund for the PhageDiag project, Belgian Vésale Bioscience BV (Namur) will develop a phage therapy...